YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study

Tan, You-Wen; Ge, Guo-Hong; Zhao, Wei; Gan, Jian-He; Zhao, Yun; Niu, Zhi-Lin; Zhang, Dong-Jun; Chen, Li; Yu, Xue- Jun; Yang, Li-Jun

doi:10.1016/S1413-8670(12)70319-7

Article information

Abstract

Objective

This study aimed to determine the natural prevalence of variants of tyrosinemethionine- aspartic acid-aspartic acid (YMDD) motif in patients with chronic hepatitis B (CHB), and to explore its relation with demographic and clinical features, hepatitis B virus (HBV) genotypes, and HBV DNA levels.

Methods

A total of 1,042 antiviral treatment naïve CHB patients (including with lamivudine [LAM]) in the past year were recruited from outpatient and inpatient departments of six centers from December 2008 to June 2010. YMDD variants were analyzed using the HBV drug resistance line probe assay (Inno-Lipa HBV-DR). HBV genotypes were detected with polymerase chain reaction (PCR) microcosmic nucleic acid cross-ELISA, and HBV deoxyribonucleic acid (DNA) was quantitated with real-time PCR. All serum samples underwent tests for HBV, HCV, and HDV with ELISA.

Results

YMDD variants were detected in 23.3% (243/1042) of CHB patients. YMDD mutation was accompanied by L180M mutation in 154 (76.9%) patients. Both wild-type HBV and YMDD variant HBV were present in 231 of 243 patients. Interestingly, 12 patients had only YIDD and/or YVDD variants without wild YMDD motif. In addition, 27.2% (98/359) of HbeAg-positive patients had YMDD mutations, which was higher than that in HbeAg-negative patients (21.2%, 145/683). The incidence of YMDD varied among patients with different HBV genotypes, but the difference was not significant. Moreover, the incidence of YMDD in patients with high HBV DNA level was significantly higher than that in those with low HBV DNA level.

Conclusion

Mutation of YMDD motif was detectable at a high rate in CHB patients in this study. The incidence of YMDD may be correlated with HBeAg and HBV DNA level.

Keywords:

YMDD

Mutations

Chronic hepatitis B

Anti-viral therapy

Full text is only aviable in PDF

References

[1.]

R. de Franchis, A. Hadengue, G. Lau, et al.

EASL International Consensus Conference on Hepatitis B. 13–14 September 2002, Geneva, Switzerland. Consensus statement (long version).

J Hepatol, 39 (2003), pp. S3-S25

Medline

[2.]

G.A. Tipples, M.M. Ma, K.P. Fischer, V.G. Bain, N.M. Kneteman, D.L. Tyrrell.

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.

Hepatology, 24 (1996), pp. 714-717

http://dx.doi.org/10.1002/hep.510240340 | Medline

[3.]

M.I. Allen, M. Deslauriers, C.W. Andrews, et al.

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

Hepatology, 27 (1998), pp. 1670-1677

http://dx.doi.org/10.1002/hep.510270628 | Medline

[4.]

P. Honkoop, H.G. Niesters, R.A. de Man, A.D. Osterhaus, S.W. Schalm.

Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns.

J. Hepatol, 26 (1997), pp. 1393-1395

Medline

[5.]

H.G. Niesters, P. Honkoop, E.B. Haagsma, R.A. de Man, S.W. Schalm, A.D. Osterhaus.

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment.

J Infect Dis, 177 (1998), pp. 1382-1385

Medline

[6.]

S. Kobayashi, T. Ide, M. Sata.

Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers.

J. Hepatol, 34 (2001), pp. 584-586

Medline

[7.]

T. Kirishima, T. Okanoue, Y. Daimon, et al.

Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment.

J Hepatol, 37 (2002), pp. 259-265

Medline

[8.]

J. Heo, M. Cho, H.H. Kim, et al.

Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection.

J Korean Med Sci, 19 (2004), pp. 541-546

http://dx.doi.org/10.3346/jkms.2004.19.4.541 | Medline

[9.]

M. Akarsu, A. Sengonul, E. Tankurt, et al.

YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.

J Hepatology, 21 (2006), pp. 1783-1788

[10.]

M. Matsuda, F. Suzuki, Y. Suzuki, et al.

Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.

J Gastroenterol, 39 (2004), pp. 34-40

http://dx.doi.org/10.1007/s00535-003-1242-4 | Medline

[11.]

M. Matsuda, F. Suzuki, Y. Suzuki, et al.

YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.

J Med Virol., 74 (2004), pp. 361-366

http://dx.doi.org/10.1002/jmv.20185 | Medline

[12.]

Z.M. Huang, Q.W. Huang, Y.Q. Qin, et al.

YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.

World J Gastroenterol, 11 (2005), pp. 867-870

Medline

[13.]

X.C. Min, X.H. Miao, S.M. Zhao, K.K. Zhao, D.G. Yang.

The spontaneous YMDD mutation rate in chronic hepatitis B patients.

Zhonghua Gan Zang Bing Za Zhi, 17 (2009), pp. 887-890

Medline

[14.]

L. Stuyver, C. Van Geyt, S. De Gendt, et al.

Line probe assay for monitoring drug resistance in hepatitis B virusinfected patients during antiviral therapy.

J Clin Microbiol, 38 (2000), pp. 702-707

Medline

[15.]

S.W. Aberle, J. Kletzmayr, B. Watschinger, B. Schmied, N. Vetter, E. Puchhammer-Stöckl.

Comparison of sequence analysis and the INO-LIPA HBV DR line probe assay for detection of lamivudineresistant hepatitis B virus strains in patients under various clinical conditions.

J Clin Microbiol, 39 (2001), pp. 1972-1974

http://dx.doi.org/10.1128/JCM.39.5.1972-1974.2001 | Medline

[16.]

S.D. Pas, R.A. de Man, E. Fries, A.D. Osterhaus, H.G. Niesters.

The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation.

J Clin Virol, 25 (2002), pp. 63-71

Medline

[17.]

H.G. Niesters, F. Zoulim, C. Pichoud, et al.

Validation of the INO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.

Antimicrob Agents Chemother, 54 (2010), pp. 1283-1289

http://dx.doi.org/10.1128/AAC.00970-09 | Medline

[18.]

Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.

The guidelines of prevention and treatment for chronic hepatitis B.

Chin Hepatol Dis J, 19 (2011), pp. 13-23

[19.]

S. Kobayashi.

Clinical characteristics of asymptomatic hepatitis B virus carriers with YMDD mutant not treated with lamivudine.

Kurume Med J, 50 (2003), pp. 87-90

Medline

[20.]

L.C. Da Silva, L.E. da Fonseca, F.J. Carrilho, V.A. Alves, R. Sitnik, J.R. Pinho.

Predictive factors for response to lamivudine in chronic hepatitis B.

Rev Inst Med Trop São Paulo, 42 (2000), pp. 189-196

Medline

[21.]

X.G. Ye, R.L. Wang, H.B. Guo.

Detection and analysis of YMDD mutate genes in patients of chronic hepatitis B before being treated.

Zhonghua Jianyan Yixue Zazhi, 25 (2002), pp. 248

[22.]

N.C. Tassopoulos, R. Volpes, G. Pastore, et al.

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant study group.

Hepatology, 29 (1999), pp. 889-896

http://dx.doi.org/10.1002/hep.510290321 | Medline

[23.]

M.F. Yuen, Y. Tanaka, C.L. Lai.

Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy.

Intervirology, 46 (2003), pp. 373-376

http://dx.doi.org/74995 | Medline

[24.]

J.M. Sánchez-Tapias, J. Costa, A. Mas, M. Bruguera, J. Rodés.

Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients.

Gastroenterology, 123 (2002), pp. 1848-1856

http://dx.doi.org/10.1053/gast.2002.37041 | Medline

[25.]

S. Rodriguez-Novoa, A. Gomez-Tato, A. Aguilera-Guirao, et al.

Hepatitis B virus genotyping based on cluster analysis of the region involved in lamivudine resistance.

J Virol Methods, 115 (2004), pp. 9-17

Medline

[26.]

D.Y. Zhou, L.Y. Lin, H. Wang, J.S. Huang.

The relationship between HBV lamivudine resistance and HBV genotypes or basic core promoter mutations.

Hepatobiliary Pancreat Dis Int, 2 (2003), pp. 85-89

Medline

[27.]

M. Yano, S. Ohkoshi, K. Suzuki, et al.

Absence of pretreatment markers that predict the emergence of YMDD mutants during lamivudine treatment – the results of a prospective multi-center study.

Hepatogastroenterology, 53 (2006), pp. 124-127

Medline

[28.]

M. Shi, Z.J. Yang, R.S. Wang, et al.

Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection.

Clin Chim Acta, 373 (2006), pp. 172-175

http://dx.doi.org/10.1016/j.cca.2006.05.023 | Medline

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter